戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 um creatinine in CNI groups was abolished by Aliskiren.
2 completely responsive to the renin inhibitor aliskiren.
3 pproaches used toward the total synthesis of aliskiren.
4 shape of the first approved renin inhibitor, aliskiren.
5 t in principal cells, which was prevented by Aliskiren.
6 diet, receiving separate escalating doses of aliskiren.
7 not differ between participants treated with aliskiren (-0.33%; 95% CI, -0.68% to 0.02%) and placebo
8 were randomly assigned to receive once-daily aliskiren 150 mg (n=437), valsartan 160 mg (455), a comb
9 7), valsartan 160 mg (455), a combination of aliskiren 150 mg and valsartan 160 mg (446), or placebo
10                                              Aliskiren 150 mg is as effective as irbesartan 150 mg in
11               The antihypertensive effect of aliskiren 150 mg was comparable to that of irbesartan 15
12                                              Aliskiren 150, 300, and 600 mg effectively lowered both
13 lind treatment with once-daily oral doses of aliskiren (150, 300, or 600 mg), irbesartan 150 mg, or p
14 g per day), Tac (0.075 mg/kg per day), CyA + Aliskiren (25 mg/kg per day), or Tac + Aliskiren for 3 w
15                                              Aliskiren 300 and 600 mg lowered mean sitting DBP signif
16  significantly more than either monotherapy (aliskiren 300 mg 9.0 mm Hg decrease, p<0.0001; valsartan
17       At week 8 endpoint, the combination of aliskiren 300 mg and valsartan 320 mg lowered mean sitti
18 ease were randomly assigned (1:1) to receive aliskiren 300 mg per day or placebo as an adjunct to ACE
19 , and body mass index >25 kg/m(2) to receive aliskiren 300 mg, losartan 100 mg, or their combination
20 shion, we randomly assigned 8561 patients to aliskiren (300 mg daily) or placebo as an adjunct to an
21          315 patients initially allocated to aliskiren, 315 allocated to amlodipine, and 617 allocate
22       318 patients were randomly assigned to aliskiren, 316 to amlodipine, and 620 to aliskiren plus
23 not differ between participants treated with aliskiren (-4.1 mm3; 95% CI, -6.27 to -1.94 mm3) and pla
24 ion, dose-dependent BP reduction occurs with aliskiren 75-300 mg once daily; at these doses, the safe
25        In total, 24.9% of patients receiving aliskiren (77 CV deaths, 153 HF rehospitalizations) and
26 d in the final efficacy analysis cohort (808 aliskiren, 807 placebo).
27                              Moreover, drugs aliskiren (a renin inhibitor) and darunavir (an HIV-1 PR
28                               Treatment with aliskiren (a renin inhibitor), but not hydralazine (a sm
29                                              Aliskiren, a direct renin inhibitor blocks these effects
30       Molecular modeling was used to develop aliskiren, a potent, low-molecular-weight, nonpeptide, d
31                                       Third, aliskiren, a renin inhibitor, does not block abnormal co
32 betes (AVOID) trial demonstrated that adding aliskiren, an oral direct renin inhibitor, at a dosage o
33           We tested whether a combination of aliskiren and amlodipine is superior to each monotherapy
34                   Treatment with irbesartan, aliskiren and amlodipine were associated with decreased
35 ng the long-term renal protective effects of aliskiren and its effects on ventricular remodeling are
36 952, reflecting the higher pharmacy costs of aliskiren and losartan ($7769), which were partially off
37 08) and TAV (64.4% vs 57.5%; P = .13) in the aliskiren and placebo groups, respectively.
38  a tolerability profile similar to that with aliskiren and valsartan alone.
39                           The combination of aliskiren and valsartan at maximum recommended doses pro
40 ention with the maximum recommended doses of aliskiren and valsartan, compared with each drug alone i
41  inhibitor pepstatin, or specific inhibitors Aliskiren and VTP23999 of the aspartyl protease renin su
42      This study suggests that canagliflozin, aliskiren, and darunavir may induce profound effects tow
43 occurred in 783 patients (18.3%) assigned to aliskiren as compared with 732 (17.1%) assigned to place
44             Noninferiority was not shown for aliskiren as compared with enalapril.
45 e of 5 or 10 mg twice daily, 2340 to receive aliskiren at a dose of 300 mg once daily, and 2340 to re
46 isk of developing hypertension and diabetes, aliskiren-based or canagliflozin-based drug design again
47 nd diastolic blood pressures were lower with aliskiren (between-group differences, 1.3 and 0.6 mm Hg,
48                        When added to an ARB, aliskiren blocks compensatory RAS activation and produce
49             iAng II synthesis was blocked by aliskiren but not by benazepril.
50  currently underway assessing the effects of aliskiren combined with an angiotensin receptor blocker
51 sion and coronary artery disease, the use of aliskiren compared with placebo did not result in improv
52                                      Fourth, aliskiren does not block dysregulated complement activit
53 althy people with the potent renin inhibitor aliskiren exceeded responses seen previously with angiot
54 CyA + Aliskiren (25 mg/kg per day), or Tac + Aliskiren for 3 weeks.
55     These findings do not support the use of aliskiren for regression or prevention of progression of
56 2 months, the event rates were 35.0% for the aliskiren group (126 CV deaths, 212 HF rehospitalization
57 come occurred in 791 patients (33.8%) in the aliskiren group (hazard ratio vs. enalapril, 0.99; 95% C
58 3 m(2) per year (95% CI -2.9 to -3.3) in the aliskiren group and -3.0 mL/min/1.73 m(2) per year (-2.8
59  impairment/renal failure were higher in the aliskiren group compared with placebo.
60 l per liter) was significantly higher in the aliskiren group than in the placebo group (11.2% vs. 7.2
61 he trial (63 in the placebo group, 53 in the aliskiren group, 43 in the valsartan group, and 37 in th
62 ren plus amlodipine group, 45 (14%) from the aliskiren group, and 58 (18%) from the amlodipine group.
63 t groups (6.5+/-14.9/3.8+/-10.1 mm Hg in the aliskiren group; 5.5+/-15.6/3.7+/-10.7 mm Hg in the losa
64 ized for HF with reduced LVEF, initiation of aliskiren in addition to standard therapy did not reduce
65 enone, atrasentan, losartan, irbesartan, and aliskiren in patients with CKD.
66                                          The Aliskiren in the Evaluation of Proteinuria in Diabetes (
67  determine the place of renin inhibition and aliskiren in the treatment of hypertension and related c
68                                              Aliskiren induced a remarkable dose-related renal vasodi
69 direct comparison studies, BP reduction with aliskiren is equivalent to commonly used antihypertensiv
70                                              Aliskiren is likely to be of most value in patients unco
71                                              Aliskiren is the first orally active inhibitor of renin
72 4.9-, 4.8-, and 5.8 g/m(2) reductions in the aliskiren, losartan, and combination arms, respectively;
73               Once-daily oral treatment with aliskiren lowers blood pressure effectively, with a safe
74                        Our data suggest that Aliskiren may be used for the prevention of CNI nephroto
75                  These results indicate that aliskiren may provide more complete and thus more effect
76 ing and were randomized to receive 300 mg of aliskiren (n = 305) or placebo (n = 308) taken orally da
77  were treated with a direct renin inhibitor, aliskiren (n = 7), or a diuretic, hydrochlorothiazide (n
78 ted adult zebrafish with the RAAS inhibitors aliskiren, olmesartan, and captopril for 7 consecutive d
79 as a low-sodium comparison and also received aliskiren on a high-sodium (200 mmol/d) diet.
80                                The effect of aliskiren on receptor-bound renin and pro-renin is the s
81 s of the ALTITUDE trial showed no benefit of aliskiren on renal outcomes (doubling of serum creatinin
82 the ALTITUDE trial to analyse the effects of aliskiren on surrogate renal outcomes in all patients an
83                  The absence of a benefit of aliskiren on the primary composite renal endpoint in the
84 RAS, RAS + treatment with either irbesartan, aliskiren or amlodipine or sham-surgery.
85 150 mg (increased to 300 mg as tolerated) of aliskiren or placebo daily, in addition to standard ther
86 s, we administered the novel renin inhibitor aliskiren over a broad dose range to fat-fed LDL recepto
87 re different between hydrochlorothiazide and aliskiren (P = 0.006 pre/post x drug).
88 nts received combination therapy with 300 mg aliskiren plus 10 mg amlodipine.
89 ebo, 5 mg amlodipine plus placebo, or 150 mg aliskiren plus 5 mg amlodipine.
90 sure (>150 mm Hg) with a combination such as aliskiren plus amlodipine can be recommended.
91 drawal of 85 patients (14%) from the initial aliskiren plus amlodipine group, 45 (14%) from the alisk
92 llocated to amlodipine, and 617 allocated to aliskiren plus amlodipine were available for analysis.
93  to aliskiren, 316 to amlodipine, and 620 to aliskiren plus amlodipine.
94 -adjusted life years, and lifetime costs for aliskiren plus losartan versus losartan.
95 Reduction in LV mass with the combination of aliskiren plus losartan was not significantly different
96 ly assigned (1:1:2) to treatment with 150 mg aliskiren plus placebo, 5 mg amlodipine plus placebo, or
97 bited by candesartan and benazepril, whereas aliskiren produced complete inhibition.
98               In patients with hypertension, aliskiren produces dose-dependent blood pressure (BP) re
99  given with an angiotensin receptor blocker, aliskiren produces significant additional BP reduction i
100 double-blind, randomized, multicenter trial (Aliskiren Quantitative Atherosclerosis Regression Intrav
101                      Two-week treatment with aliskiren (renin inhibitor) or losartan (AT1 antagonist)
102 sartan (ARB), benazepril (ACE inhibitor), or aliskiren (renin inhibitor).
103                                              Aliskiren showed no beneficial effect on hard renal outc
104                                              Aliskiren showed safety and tolerability comparable to t
105 oximately 300 mg once daily; at these doses, aliskiren shows placebo-like tolerability.
106                                  Conversely, aliskiren significantly decreased ace2 expression in the
107                                              Aliskiren significantly decreased progression (hazard ra
108                                              Aliskiren suppresses PRA when given either as monotherap
109 first 6 months was significantly larger with aliskiren than with placebo (-2.5 mL/min/1.73 m(2), 95%
110                    We compared the effect of aliskiren, the first orally active direct renin inhibito
111                           The development of aliskiren, the first orally effective renin inhibitor, u
112       We estimated the cost-effectiveness of aliskiren to be $30,500 per quality-adjusted life year g
113  with chronic heart failure, the addition of aliskiren to enalapril led to more adverse events withou
114                        In conclusion, adding aliskiren to losartan and optimal therapy in patients wi
115                         We found that adding aliskiren to losartan increased time free of ESRD, life
116 ients with diabetic nephropathy, addition of aliskiren to losartan, 100 mg resulted in a 20% greater
117 ted, there was a greater benefit from adding aliskiren to natriuretic drugs than to other blockers of
118                              The addition of aliskiren to standard therapy with renin-angiotensin sys
119 inhibitor enalapril with the renin inhibitor aliskiren (to test superiority or at least noninferiorit
120                                        After aliskiren treatment, supine MSNA remained unchanged (69
121  morbidity in Heart Failure) and ATMOSPHERE (Aliskiren Trial to Minimize Outcomes in Patients with He
122  Morbidity in Heart Failure) and ATMOSPHERE (Aliskiren Trial to Minimize Outcomes in Patients With He
123 y in Heart Failure) or the ATMOSPHERE trial (Aliskiren Trial to Minimize Outcomes in Patients With He
124 up, 43 in the valsartan group, and 37 in the aliskiren/valsartan group), mainly due to lack of therap
125 1.73 m(2) per year, 95% CI -3.0 to -2.6 with aliskiren vs -3.1 mL/min/1.73 m(2) per year, 95% CI -3.3
126                  These findings suggest that aliskiren was as effective as an angiotensin receptor bl
127                                              Aliskiren was as effective as losartan in promoting LV m
128                                              Aliskiren was as effective as losartan in reducing LV ma
129                                              Aliskiren was found to be effective either as monotherap
130 secondary objective was to determine whether aliskiren was noninferior to losartan in reducing LV mas
131 As another functional index of the effect of aliskiren, we found significant natriuresis on both diet
132 is hoped that long-term outcome studies with aliskiren will finally allow this question to be answere
133 and safety of the novel oral renin inhibitor aliskiren with placebo and an active comparator.
134 on Intravascular Ultrasound Study) comparing aliskiren with placebo in 613 participants with coronary
135 lasma renin activity (PRA) is observed after aliskiren withdrawal.
136 lockade with the direct oral renin inhibitor aliskiren would produce renal vascular responses exceedi
137 ne whether use of the direct renin inhibitor aliskiren would reduce cardiovascular and renal events i

 
Page Top